MONTREAL, June 18, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer ("CDO") and consequently he is stepping down from the Company's Board of Directors.
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.